Human papillomavirus infection is most common sexually transmitted infection caused by HPV-related cancers such as cervical and genital cancer. Human papillomavirus infection vaccines are used to prevent genital wart, anal cancer, cervical cancer, and vaginal cancer. Three commercially available HPV prevention vaccine such as Gardasil and Gardasil 9 by Merck & Co., Inc. and Cervarix by GlaxoSmithKline plc, are proven to be highly effective in preventing of HPV infection and genital precancerous lesions. The adoption of preventive vaccines shifted the paradigm of diseases, and are expected to have a major impact in reducing the burden of cervical cancer, HPV-associated malignancies, and benign tumors. The key factors driving growth of the human papillomavirus infection vaccine market include large number of pipeline products, increasing research for therapeutic vaccine, governmental initiative for immunization program, and high prevalence of HPV-related infectious disease.

Request For Sample Pdf Of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1588

Human Papillomavirus (HPV) Infection Vaccines Market Driver
Large number of clinical trials conducted by pharmaceutical and biopharmaceutical companies are expected to fuel growth of the HPV infection vaccine market during the forecast period. For instance, Merck & Co., Inc., is conducting Phase III clinical trial for it quadrivalent human papillomavirus recombinant vaccine for type 6, 11, 16, and 18. Moreover, Shanghai Bovax Biotechnology Co., Ltd., is engaged in evaluating safety and primary immunogenicity of the quadrivalent human papillomavirus vaccine in female population of China. Currently studies are in phase I clinical trial. Furthermore, Serum Institute of India Pvt. Ltd., is developing tetravalent HPV vaccine, which is expected to provide protection of around 90% against HPV infections, which are prevalent in the emerging economies such as India and China.

Moreover, increasing research on therapeutic vaccine for treatment of HPV infection to address unmet medical need is expected to boost growth of the human papilloma virus (HPV) infection vaccines market. For instance, Profectus BioSciences, Inc., is engage in developing GeneVax prime/VesiculoVax, a therapeutic vaccine for HPV infection. The vaccine is expected to be effective against seven HPV types. Moreover, Inovio Pharmaceuticals, Inc., is investigating VGX-3100 as candidate for immunotherapy to demonstrate efficacy against cervical HSIL associated with HPV-16 and HPV-18. VGX-3100 is divalent DNA plasmid-based therapeutic vaccine, which completed phase 2b clinical trial in 2015 and initiated phase 3 in June 2017.

Governmental and non-governmental organization plays important role in increasing awareness through immunization program, in turn driving growth of the human papillomavirus infection vaccine market. For instance, in 2012, the Global Alliance for Vaccines and Immunization (GAVI) support for HPV vaccine introduction targeted to reach 30 million girls in emerging economies by 2020. In 2016, Joint UN Global Programme was set up for prevention of cervical cancer, which includes vaccination in high disease burden countries.

Human Papillomavirus (HPV) Infection Vaccines Market Regional Analysis
Regional segmentation of human papillomavirus (HPV) infection vaccine market by Coherent Market Insights, includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America comprises major share of the human papillomavirus infection treatment vaccine market, owing to high prevalence of cervical cancer, local market players and increasing governmental initiatives, followed by Europe. For instance, according to WHO 2016, currently 86% of America and 62% of European region girls have access to free HPV vaccination. Moreover, incidence of cervical cancer in Europe was 58,348 individuals per million in 2012.

Human Papillomavirus (HPV) Infection Vaccines Market Key Players

Major players operating in the HPV infection vaccine market include Merck & Co., Inc. and GlaxoSmithKline plc. The companies having the candidate for HPV vaccines are Shanghai Bovax Biotechnology Co., Ltd., Profectus BioSciences, Inc., 2A Pharma AB and ISA Pharmaceuticals.

Click To Read More On Human Papillomavirus (HPV) Infection Vaccines Market

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at [email protected]
https://www.coherentmarketinsights.com/phase-xs/

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.